bg
Sopharma shareholders voted dividend yielding approx. 3%
Generic pharma producer Sopharma’s shareholders voted BGN 0.11 dividend per share at the general shareholders’ meeting held on 15th June, 2018. The dividend yields 2.59% at current quotes.
New research report: Sopharma Trading – set for double expansion in 5 years
With 8.2% CAGR for the last 10 years and 7% average DY in the last 7 years, Sopharma Trading firmly leads the Bulgarian pharmaceuticals wholesale market. Following strong acquisition spree on the local and export markets in 2017, the Company is all set for a major expansion to nearly double in size in next 5… Read more
Sopharma Trading standalone top line expands by 10.4% in Q1 2018
Pharmaceuticals wholesaler Sopharma Trading expanded its standalone top line by 10.4% to BGN 181.7m in Q1’18 on higher sales in all segments, according to the Company’s financial statements for Q1’18.
Sopharma to vote BGN 39m profit to be distributed as dividend
Leading generic pharmaceuticals producer Sopharma proposed a BGN 0.11 dividend per share (DPS), the Company disclosed in a filing to the Trade Registry. This comes very short of ELANA Trading Research team BGN 0.12 DPS estimate.
New research report: Sopharma’s expansion mode is on
The biggest vertically integrated human health pharmaceutical group in Bulgaria Sopharma booked record performance in 2017 with the top line hitting BGN 1bn and best EBITDA ever on strong organic and M&A driven growth. Individual bottom line margins healthy above historical and peer averages at 20%+ as cost and group optimization kicked in.
Sopharma hit record in revenues for FY 2017
Leading pharma group Sopharma (3JR BU) hit record BGN 1bn in revenues for FY2017, marking a 15.1% y/y growth, according to Company’s consolidated financial statements for Q4’17. In FY2017, the Company’s EBITDA grew 17.5% y/y reaching BGN 86.6m, while EBIT was up by 25.4% y/y to BGN 56.3m.
Sopharma and Unipharm shareholders approve merger
Shareholders of Bulgaria’s leading generic drugs producer Sopharma (3JR BU) and Unipharm (59X BU) approve merger, according to а regulatory note from the two extraordinary shareholders’ meetings held on 23rd Feb 2018.
Sopharma’s smoking cessation drug with positive preliminary clinical data in the US
Sopharma’s (ELANA BG Trader: 3JR BU) smoking cessation drug with positive preliminary clinical trial data in the US, the Company’s American partner Achieve Life Sciences (NASDAQ: ACHV) announced in a statement.
Sopharma Trading plans further diversification and dynamic growth for the next three years
Sopharma Trading plans to diversify its business model and expand its market shares, the company’s CEO Dimitar Dimitrov announced in an interview in Bulgarian media Investor.bg.
Sopharma posted 13% y/y rise in top line for FY2017
The leading pharma producer Sopharma posted 13% y/y growth of its revenues for FY2017, the Company announced in its regular monthly bulletin. Overall for 2017, the group increased its domestic sales by 3% and its export advanced by 21% y/y as Russian and Ukrainian markets began to recover.
